NasdaqGS:ADPTLife Sciences
Adaptive Biotechnologies Q1 Loss Deepens Again And Tests Profitability Improvement Narrative
Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting...